Dr. Babar is Chief Business & Financial Officer at Sudo Biosciences and serves on the Board of Directors for Rare Genomics Institute.

Previously, Imran was the Chief Business Officer of Cydan II, an NEA and Pfizer Ventures-backed orphan drug accelerator. He is also co-founder of several companies including Arvada Therapeutics. Prior to Cydan, Imran was on the venture capital team at OrbiMed Advisors where he was involved with numerous companies including True North Therapeutics (acquired), Audentes Therapeutics (acquired), 89bio (public), Arvinas Therapeutics (public), and Dimension Therapeutics (acquired), among others.

Prior to that, Imran worked as an associate at Cowen & Company on the biotechnology equity research team. Imran is also co-founder and a board director for Rare Genomics Institute, a 501(c)3 nonprofit dedicated to helping patients with rare diseases.

Imran completed his PhD in Molecular Biology at Yale and his BA in Biology at Carleton College.